-
Mashup Score: 1Glaucoma Physician - May 12, 2023 - 11 month(s) ago
May 12, 2023 ViaLase Announces Positive Results of First-In-Human Study of Femtosecond Laser Image-Guided High-Precision Trabeculotomy (FLigHT) ViaLase has announced positive results of the first-in-human study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) performed with the ViaLase technology. In a press release, the…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 0Glaucoma Physician - May 12, 2023 - 11 month(s) ago
May 12, 2023 ViaLase Announces Positive Results of First-In-Human Study of Femtosecond Laser Image-Guided High-Precision Trabeculotomy (FLigHT) ViaLase has announced positive results of the first-in-human study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) performed with the ViaLase technology. In a press release, the…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
Glaukos Corporation has received notification from the FDA acknowledging the previously submitted New Drug Application (NDA) for iDose TR is sufficiently complete to permit a substantive review. Read more in the eUpdate: https://t.co/iImEBNwTbd #glaucoma https://t.co/9DMyrp2PH1
-
-
Mashup Score: 0Glaucoma Physician - May 12, 2023 - 11 month(s) ago
May 12, 2023 ViaLase Announces Positive Results of First-In-Human Study of Femtosecond Laser Image-Guided High-Precision Trabeculotomy (FLigHT) ViaLase has announced positive results of the first-in-human study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) performed with the ViaLase technology. In a press release, the…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
ViaLase has announced positive results of the first-in-human study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) performed with the ViaLase technology. Read more in the eUpdate: https://t.co/iImEBNwTbd #glaucoma https://t.co/LVpLLIIoDB
-
-
Mashup Score: 0Glaucoma Physician - MIGS Minute Video Channel - 11 month(s) ago
The MIGS Minute Video Channel is a highly informative monthly video series that will highlight key developments and clinical insights in glaucoma surgery and beyond. Hosted by I. Paul Singh, MD, the video series will feature leading clinicians who will share perspective and insight on the latest innovations as well as experience and case studies. Part 5 Inder Paul Singh, MD and…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
In video 5 on the MIGS Minute Video Channel, Inder Paul Singh, MD, and Arsham Sheybani, MD, discuss IOP variability and the cause of pressure rising. Watch at https://t.co/SmEoPf3zKX #ophthotwitter #glaucoma #ophthalmology https://t.co/ZZJCO6ZTtn
-
-
Mashup Score: 0
■ Lumibird Medical has launched a fully integrated Q-switched Nd:YAG and frequency doubled Nd:YAG laser for anterior-segment YAG and glaucoma indications. The company stated that the Tango Reflex Neo by Ellex features second-generation Reflex technology with true coaxial illumination. The feature reportedly enhances visualization of anterior and posterior segments. According to a company news…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
Lumibird Medical has launched a fully integrated Q-switched Nd:YAG and frequency doubled Nd:YAG laser for anterior-segment YAG and #glaucoma indications. Read more from the news in the current issue: https://t.co/LBXyqcK2q6 https://t.co/u8Zqws5uBA
-
-
Mashup Score: 0Glaucoma Physician - FDA Accepts NDA for MydCombi Delivered via Optejet - 12 month(s) ago
■ The FDA has accepted Eyenovia’s NDA for MydCombi ophthalmic spray, according to the company. The drug-device combination product includes a proprietary tropicamide and phenylephrine combination for in-office mydriasis administered via the investigational Optejet drug delivery technology. “If approved, MydCombi would be the first commercial product to leverage our proprietary Optejet drug…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
Eyenovia’sMydCombi ophthalmic spray has received an NDA approval from the FDA. The drug-device combination for in-office mydriasis is administered via the investigational Optejet drug delivery technology. Read more in the news from the current issue. https://t.co/tVBY07wGnB https://t.co/gjZvLlT4MG
-
-
Mashup Score: 0Glaucoma Physician - Results for iDose TR Exchange Trial Show Good Safety and Tolerability - 12 month(s) ago
■ A second administration of iDose TR and removal of the original iDose TR implant was safe and well tolerated in an exchange trial, Glaukos reported. The second implant demonstrated a favorable safety profile over 12 months and no subject had >30% endothelial cell loss during the extended evaluation period of more than 5 years. The company plans to submit an NDA in the coming months. Glaukos…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
A second administration of iDose TR and removal of the original iDose TR implant was safe and well tolerated in an exchange trial. Read more in the news from the current issue: https://t.co/8zSUlLZdK9 #glaucoma https://t.co/ROC9tSadgE
-
-
Mashup Score: 0Glaucoma Physician - Phase 2b Study of MediPrint Proprietary Drug-Eluting Contact Lens for Glaucoma Initiated - 12 month(s) ago
■ MediPrint Ophthalmics has begun the SIGHT-2 dose-finding phase 2b study for its proprietary drug-eluting contact lens for glaucoma. This SIGHT-2 clinical program is designed to assess dose optimization. SIGHT-1 validated the company’s process and bimatoprost-releasing contact lenses for treating patients with mild to moderate glaucoma and ocular hypertension. “This is a key milestone in…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
MediPrint Ophthalmics has begun the SIGHT-2 dose-finding phase 2b study for its proprietary drug-eluting contact lens for #glaucoma. Read more in the news from the current issue: https://t.co/4VafP9Mchs https://t.co/okAnU2Ese7
-
-
Mashup Score: 0Glaucoma Physician - Positive Phase 3 Results for TearClear’s Proprietary Preservative-free Latanoprost - 12 month(s) ago
■ TearClear’s latanoprost ophthalmic solution 0.005% met the primary and all secondary endpoints in the CLEAR phase 3 trial, and the company plans to file an NDA this year. The product “will offer patients the first and only means of delivering preservative-free doses of latanoprost from conventional multidose bottles,” according to the company. The product contains the preservative BAK while in…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
TearClear’s latanoprost ophthalmic solution 0.005% met the primary and all secondary endpoints in the CLEAR phase 3 trial. Read more in the news from the current issue. https://t.co/2UTSYWoghx https://t.co/7dLMvD6r8V
-
-
Mashup Score: 0Glaucoma Physician - MIGS Minute Video Channel - 12 month(s) ago
The MIGS Minute Video Channel is a highly informative monthly video series that will highlight key developments and clinical insights in glaucoma surgery and beyond. Hosted by I. Paul Singh, MD, the video series will feature leading clinicians who will share perspective and insight on the latest innovations as well as experience and case studies. Part 5 Inder Paul Singh, MD and…
Source: Glaucoma PhysicianCategories: Latest Headlines, OphthalmologyTweet-
In the latest segment of the MIGS Minute video channel, Inder Paul Singh, MD, and Arsham Sheybani, MD, discuss IOP variability and the cause of pressure rising. https://t.co/2nZdYr3BXI #ophthalmology #glaucoma #ophthotwitter https://t.co/Xc31YBX8zF
-
An analysis of medical records of 16,789 mild glaucoma MIGS patients in the IRIS Registry showed that patients in the OMNI technology cohort experienced the greatest average medication reduction. Read more un the eUpdate: https://t.co/iImEBNwTbd https://t.co/izZR09XwB1